Company Profile
|
BICO Group AB
(OTC: BCCOY)
|
1:30 PM UTC, 06/14/24 | |||
|---|---|---|---|---|
| Last: $0.98 | Change: -0.00 | %Change: -0.01% | Volume: 240 | |
Detailed Quote
M = Million B = Billion
Price Performance
Management Effectiveness
Profitability
| Open: | $ 0.98 | Volume: | 240 | |
|---|---|---|---|---|
| High: | $ 0.98 | Yield(%) | 0.00 | |
| Low: | $ 0.98 | P/E Ratio (ttm): | n/a | |
| Dividend ($): | n/a | Market Cap ($): | 290.11M | |
| EPS ($) | -0.63 | Shares Out: | 276.30M |
| % Price Change (last 4 weeks): | -0.85 |
|---|---|
| % Price Change (last 13 weeks): | -1.97 |
| % Price Change (last 26 weeks): | -29.28 |
| % Price Change (last 52 weeks): | 7.39 |
| % Price Change (year to date): | -25.69 |
| Return on Equity (%): | -27.16 |
|---|---|
| Return on Assets (%): | -17.68 |
| Return on Invested Capital (%): | -7.38 |
| Gross Profit Margin (%): | -13.23 |
|---|---|
| Net Profit Margin (%): | -73.51 |
| Operating Profit Margin (%): | -13.23 |
Price & Volume
Company Information
Per Share Data
Valuation Ratios
Financial Strength
|
|
|
| 50-day Moving Average: | $n/a |
|---|---|
| 200-day Moving Average: | $n/a |
| Avg. Daily Vol. (last 50 days): | n/a |
| Avg. Daily Vol. (last 200 days): | n/a |
| 52-wk high: | $1.55 |
| 52-wk low: | $0.77 |
| Bid: | $n/a |
| Ask: | $n/a |
|
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. It operates through the following segments: Bioprinting, Biosciences, Bioautomation, and Group. The Bioprinting segment includes 3D bioprinters and bioinks with a wide range of technologies for different demanding applications, resolutions, and volume and speed requirements, as well as services focused on accelerating drug discovery and development with advanced tissue imaging and cell culture services. The Biosciences segment focuses on supplying advanced lab instrumentation and smart workflow connectivity software to analyze data from applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics such as genomics. The Bioautomation segment offers scientific instruments and solutions for scalable manufacturing of diagnostics, as well as consumables to enable single-cell and other workflows. The Group segment is involved in the group’s administration and shareholder costs. The company was founded by Erik Paul Gatenholm and Hector Daniel Martinez Avila in March 2015 and is headquartered in Gothenburg, Sweden.
|
| Earnings (1year) ($): | n/a |
|---|---|
| Annual Dividend ($): | 0.00 |
| Current P/E Ratio (ttm): | n/a |
| Book Value ($): | 1.72 |
| Cash Flow ($): | -0.50 |
| Price/Earnings (x): | n/a |
|---|---|
| Price/Sales (x): | 1.88 |
| Price/Book (x): | 0.82 |
| Price/Cash Flow (x): | 23.74 |
| Quick Ratio (x): | 1.91 |
|---|---|
| Current Ratio (x): | 2.41 |
| LT Debt/Equity (x): | 38.02 |
| Total Debt/Equity (x): | 40.11 |
